These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 2993692

  • 1. [Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer].
    Negishi Y, Furuno K, Sano Y, Hirata T, Utsunomiya A, Nakajima H, Okabe K, Shimizu K, Akiya K, Fujiwara Y.
    Gan No Rinsho; 1985 May; 31(6 Suppl):655-63. PubMed ID: 2993692
    [Abstract] [Full Text] [Related]

  • 2. [The clinical significance of CA125 in patients with gynecological tumors--a comparative study on CA125 and other tumor markers].
    Suzumori K, Yasui Y, Asai H, Hisaoka T, Mizuno K, Yagami Y.
    Gan No Rinsho; 1985 May; 31(5):544-8. PubMed ID: 3860666
    [Abstract] [Full Text] [Related]

  • 3. [Significance of CA 125 antigen levels in patients with ovarian cancer].
    Shimizu Y, Fujiwara H, Akagaki E, Hirota K, Kono M, Irie T, Miura S, Okudaira Y.
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
    [Abstract] [Full Text] [Related]

  • 4. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
    Suzuki H, Teshima K, Noda K.
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
    [Abstract] [Full Text] [Related]

  • 5. [Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms].
    Yabushita H, Masuda T, Hattori A, Noguchi M, Ito Y, Nakanishi M, Ishihara M.
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1883-92. PubMed ID: 2997349
    [Abstract] [Full Text] [Related]

  • 6. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
    Negishi Y, Iwabuchi H, Sakunaga H, Sakamoto M, Okabe K, Sato H, Asano G.
    Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375
    [Abstract] [Full Text] [Related]

  • 7. [Clinical significance of new tumor marker CA 125 in gynecological cancer--particularly usefulness in diagnosis of ovarian cancer].
    Kimura E, Murae M, Koga R, Odawara Y, Nakabayashi Y, Yokoyama K, Nakata H, Totake T, Ochiai K, Yasuda M.
    Nihon Sanka Fujinka Gakkai Zasshi; 1984 Nov; 36(11):2121-8. PubMed ID: 6595320
    [Abstract] [Full Text] [Related]

  • 8. [Clinical significances of tissue polypeptide antigen in patients with gynecological malignancies].
    Ueda M, Sudo N, Furuya M, Arakawa O, Ikarashi T.
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Nov; 37(11):2361-8. PubMed ID: 3001201
    [Abstract] [Full Text] [Related]

  • 9. Tumor-associated antigen Ca 125 before and during the treatment of ovarian carcinoma.
    Kivinen S, Kuoppala T, Leppilampi M, Vuori J, Kauppila A.
    Obstet Gynecol; 1986 Apr; 67(4):468-72. PubMed ID: 3008051
    [Abstract] [Full Text] [Related]

  • 10. [A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers].
    Kataoka A, Yakushiji M.
    Nihon Gan Chiryo Gakkai Shi; 1990 Jan 20; 25(1):47-54. PubMed ID: 2157782
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Value of the TAG-72 (CA 72-4) tumor marker in primary diagnosis of ovarian carcinoma. A comparison with the established CA-125 marker].
    Zeimet AG, Guadagni F, Marth C, Amato T, Müller-Holzner E, Huter O, Daxenbichler G, Dapunt O.
    Geburtshilfe Frauenheilkd; 1995 Apr 20; 55(4):195-9. PubMed ID: 7789707
    [Abstract] [Full Text] [Related]

  • 13. [Value of CA 125 in comparison to conventional tumor markers in ovarian cancer].
    Paulick R, Kaesemann H, Caffier H.
    Geburtshilfe Frauenheilkd; 1986 Aug 20; 46(8):509-14. PubMed ID: 2875919
    [Abstract] [Full Text] [Related]

  • 14. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
    Hasholzner U, Baumgartner L, Stieber P, Meier W, Hofmann K, Fateh-Moghadam A.
    Anticancer Res; 1994 Aug 20; 14(6B):2743-6. PubMed ID: 7532929
    [Abstract] [Full Text] [Related]

  • 15. A comparative study of immunosuppressive acidic protein (IAP), CA 125 and acute-phase proteins as parameters for ovarian cancer monitoring.
    Koebl H, Tatra G, Bieglmayer C.
    Neoplasma; 1988 Aug 20; 35(2):215-20. PubMed ID: 3259680
    [Abstract] [Full Text] [Related]

  • 16. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer.
    Kamiya N, Mizuno K, Kawai M, Kano T, Furuhashi Y, Tomoda Y.
    Obstet Gynecol; 1990 Sep 20; 76(3 Pt 1):417-21. PubMed ID: 2381619
    [Abstract] [Full Text] [Related]

  • 17. Proliferation tissue polypeptide antigen distinguishes malignant mucinous cystadenocarcinomas from benign cystic tumors and pseudocysts.
    Yang JM, Southern JF, Warshaw AL, Lewandrowski KB.
    Am J Surg; 1996 Jan 20; 171(1):126-9; discussion 129-30. PubMed ID: 8554126
    [Abstract] [Full Text] [Related]

  • 18. [Clinical significance of serum sialyl Tn antigen in patients with gynecological cancer. STN Study Group].
    Noda K, Shiota M, Tanizawa O, Inoue M, Tenjin Y, Sugishita T, Yakushiji M, Miyoshi T, Nozawa S, Sakuma T.
    Gan To Kagaku Ryoho; 1991 Jul 20; 18(8):1287-96. PubMed ID: 2069400
    [Abstract] [Full Text] [Related]

  • 19. CA 125 and carcinoembryonic antigen levels in cyst fluid, ascites and serum of patients with ovarian neoplasms.
    Harłozińska A, Bar JK, Gawlikowski W, Richter R, Cisło M.
    Ann Chir Gynaecol; 1991 Jul 20; 80(4):368-75. PubMed ID: 1667567
    [Abstract] [Full Text] [Related]

  • 20. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors].
    Shimizu Y, Akagaki E, Hirota K, Kono M, Miura S, Okudaira Y.
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec 20; 37(12):2813-20. PubMed ID: 3866801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.